Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multidrug resistance in acute leukemia: a conserved physiologic function.

A F List1, C M Spier

  • 1Department of Internal Medicine, University of Arizona, Tucson.

Leukemia & Lymphoma
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.

Leukemia·2023
Same author

Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.

Leukemia·2017
Same author

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.

Leukemia·2016
Same author

Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.

Leukemia & lymphoma·2016
Same author

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

Leukemia·2015
Same author

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

Multidrug resistance (MDR) is a key factor in acute leukemia treatment failure. Overexpression of the mdr1 gene and P-glycoprotein in leukemia cells predicts poor response to chemotherapy.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Chemotherapy resistance is a major challenge in treating adult acute leukemias.
  • Understanding drug resistance mechanisms is crucial for developing better therapies.
  • The multidrug resistance (MDR) phenotype is a clinically relevant mechanism of resistance.

Purpose of the Study:

  • To investigate the role of multidrug resistance (MDR) in acute leukemias.
  • To explore the expression of the mdr1 gene and P-glycoprotein in different acute leukemia subtypes.
  • To determine the prognostic significance of MDR in acute myeloid leukemia (AML).

Main Methods:

  • Analysis of mdr1 gene and P-glycoprotein expression in leukemia cells.
  • Prospective studies in AML patients treated with conventional chemotherapy.

Related Experiment Videos

  • Investigation of mdr1 regulation in normal hematopoietic cells.

    • Main Results:

    • MDR phenotype is frequently detected in secondary AML and poor-risk acute lymphoblastic leukemia.
    • MDR overexpression is an independent predictor of treatment response and survival in AML.
    • mdr1 gene regulation in leukemia mirrors its regulation in normal hematopoietic cells.

    Conclusions:

    • MDR is a significant factor contributing to treatment failure in acute leukemias.
    • The mdr1 gene and P-glycoprotein are important biomarkers for predicting outcomes in AML.
    • Therapeutic strategies targeting MDR reversal are under investigation for high-risk leukemias.